Abstract

BackgroundThe oncogenic role of the fibroblast growth factor receptor (FGFR) has been recognized in a number of different cancer types. However, the prognostic significance of FGFRs has not been elucidated yet in cervical cancer. In the present study, we investigate the expression of FGFRs and their prognostic value in cervical cancer patients.MethodsFGFR1, FGFR2, FGFR3, and FGFR4 expression was determined by immunohistochemistry in conjunction with quantitative digital image analysis of 336 formalin-fixed, paraffin-embedded cervical cancer tissues and 61 normal cervical tissues, as well as NCI60 cell microarray. Subsequently, the association between clinicopathological characteristics and patient survival was assessed.ResultsFGFRs proteins were differentially expressed in the NCI60 cell line panel and showed considerable correlation between protein and mRNA expression. The expression of FGFR1, FGFR2, and FGFR4 were higher in cancer tissues than in normal tissues, whereas the expression of FGFR3 was higher in normal tissues. FGFR1 was highly expressed in adeno-/adenosquamous carcinoma (P = 0.020), while FGFR2, FGFR3, and FGFR4 expression were more prominent in squamous cell carcinoma (P < 0.001, P < 0.001, and P = 0.020, respectively). FGFR2 expression was significantly higher in small sized tumors (P = 0.020). Additionally, high FGFR2 and FGFR4 were correlated with negative lymph node metastasis (P = 0.048 and P = 0.040, respectively). FGFR1, FGFR2, and FGFR3 were highly expressed in tumors without parametrial involvement (P = 0.030, P = 0.005, and P = 0.010, respectively). In survival analysis, high expressions of FGFR2, FGFR3, and FGFR4 was associated with longer disease-free survival (P = 0.006, P = 0.035, P = 0.001, respectively) and overall survival (P = 0.003, P = 0.002, P = 0.003, respectively). Notably, the co-expression of all three FGFRs was significantly associated with favorable disease-free survival (P < 0.001) and overall survival (P < 0.001), compared to the negative expressions of the three FGFRs. The prognostic significance persisted in the cox regression analysis.ConclusionsThe frequent expression of members of the FGFR family in cervical cancer suggests they may have prognostic and therapeutic relevance.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-016-0874-0) contains supplementary material, which is available to authorized users.

Highlights

  • The oncogenic role of the fibroblast growth factor receptor (FGFR) has been recognized in a number of different cancer types

  • Clinical factors such as International Federation of Gynecology and Obstetrics (FIGO) stage, lymph node metastasis, and tumor size may serve as prognostic markers, they are insufficient in accurately predicting recurrence and survival

  • In the present study, we investigated the prognostic significance of FGFR1, FGFR2, FGFR3, and FGFR4 expression in a large cohort of cervical cancer patients

Read more

Summary

Introduction

The oncogenic role of the fibroblast growth factor receptor (FGFR) has been recognized in a number of different cancer types. Preventive vaccination and screening are good in prevention, invasive cancer continues to occur, even among women who have access to cancer screening, and the prognosis remains poor in patients with a bulky tumor or adenocarcinoma histology [3,4,5] Clinical factors such as International Federation of Gynecology and Obstetrics (FIGO) stage, lymph node metastasis, and tumor size may serve as prognostic markers, they are insufficient in accurately predicting recurrence and survival. The FGF/FGFR system is responsible for multiple cellular functions, including proliferation, differentiation, survival, and motility [6,7,8,9] Considering these functions, it is no surprise they are susceptible to aberration in cancer cells [10]. FGFR2 expression has been reported to be associated with cell growth and progression of cervical dysplasia [22, 23]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call